Poplar Therapeutics closed a $45M Series A extension to advance its anti-IgE therapy.
Poplar Therapeutics is a clinical-stage immunology company developing a new class of anti-IgE therapy to challenge convention in allergic disease treatment
Poplar Therapeutics is a clinical-stage immunology company developing a new class of anti-IgE therapy to challenge convention in allergic disease treatment. Its lead program, PHB-050, is a next-generation anti-IgE antibody with a unique triple-action design currently being studied in atopic diseases.